Risk factors and survival outcomes in children with early cardiotoxicity after allogeneic hematopoietic stem cell transplantation
- PMID: 38709259
- DOI: 10.1007/s00277-024-05787-9
Risk factors and survival outcomes in children with early cardiotoxicity after allogeneic hematopoietic stem cell transplantation
Abstract
Cardiotoxicity in children is a potentially fatal complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT); therefore, early identification of risk factors can improve patient prognosis. However, there are few data on the clinical characteristics of early-stage cardiotoxicity in children after allo-HSCT. We conducted a retrospective single-center study of pediatric patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) between January 2016 and December 2022 at the Children's Hospital Affiliated with Chongqing Medical University to evaluate the clinical characteristics of early cardiac events (ECEs) after allo-HSCT and their impact on survival outcomes. We enrolled 444 patients who underwent allo-HSCT-304 males (68%) and 140 females (32%)-with a median age of 3.3 years (1.8-6.5 years) at transplantation. We found that 73 patients (16.4%) had ECEs after allo-HSCT. The ECEs included valvular disease (n = 46), pericardial effusion (n = 38), arrhythmia (n = 9), heart failure (n = 16), and dilated cardiomyopathy (n = 1). Female sex, age ≥ 6 years, body mass index (BMI) < 16 kg/m2 and HLA-type mismatches were risk factors for ECEs. We designed a stratified cardiac risk score that included these risk factors, and the higher the score was, the greater the cumulative incidence of ECEs. The occurrence of an ECE was closely associated with a lower overall survival (OS) rate and greater nonrelapse mortality (NRM). In addition, stratified analysis based on the number of combined ECEs showed that the greater the number of combined ECEs was, the more significant the negative impact on OS rates.
Keywords: Allogeneic hematopoietic stem cell transplantation; Children; Early cardiotoxicity; Risk factors; Survival outcomes.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
References
-
- Balassa K, Danby R, Rocha V (2019) Haematopoietic stem cell transplants: principles and indications. Br J Hosp Med (Lond) 80(1):33–39. https://doi.org/10.12968/hmed.2019.80.1.33 - DOI - PubMed
-
- Barriga F, Ramírez P, Wietstruck A, Rojas N (2012) Hematopoietic stem cell transplantation: clinical use and perspectives. Biol Res 45(3):307–316. https://doi.org/10.4067/S0716-97602012000300012 - DOI - PubMed
-
- Zhao Y, He R, Oerther S, Zhou W, Vosough M, Hassan M (2022) Cardiovascular complications in hematopoietic stem cell transplanted patients. J Pers Med 12(11):1797. https://doi.org/10.3390/jpm12111797 - DOI - PubMed - PMC
-
- Bhatia S (2011) Long-term health impacts of hematopoietic stem cell transplantation inform recommendations for follow-up. Expert Rev Hematol 4(4):437–454. https://doi.org/10.1586/ehm.11.39 - DOI - PubMed - PMC
-
- Ohmoto A, Fuji S (2021) Cardiac complications associated with hematopoietic stem-cell transplantation. Bone Marrow Transplant 56(11):2637–2643. https://doi.org/10.1038/s41409-021-01427-2 - DOI - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials